Business Wire

Pyramid Analytics added to the DoD’s Tradewind Solutions Marketplace

8.6.2023 16:07:00 EEST | Business Wire | Press release

Share

Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, is pleased to announce that its Pyramid Decision Intelligence Platform has been added to the Tradewind Solutions Marketplace, DoD’s digital environment of post-competition, readily awardable, technology solution pitch videos. The Tradewind Solutions Marketplace is the flagship offering of Tradewind, DoD’s suite of tools and services designed to accelerate the procurement and adoption of AI/ML, digital, and data analytics solutions across the DoD. Tradewind sits in the DoD’s Chief Digital Artificial Intelligence Office (CDAO).

The Pyramid Platform provides comprehensive, advanced analytics capabilities, including data pipelines and preparation (with embedded machine learning), enterprise and self-service data analytics, dashboarding (with built-in AI and chat-bots), and data science.

Pyramid’s platform was rated as “Awardable” and added to the Tradewind Solutions Marketplace. Solutions selected for the Marketplace, including the Pyramid Decision Intelligence Platform, have been assessed and vetted through competitive procedures, which satisfy the competition requirements of the Federal Acquisition Regulation (FAR), the Defense Federal Acquisition Regulation Supplement (DFARS), and the Statutes, Policies, and guidance applicable to the DoD’s Other Transaction Authorities.

Key points

  • Pyramid’s platform is now listed on the Tradewind Solutions Marketplace, DoD’s digital platform for sourcing AI/ML, digital, and data analytics solutions.
  • The DoD and the broader Defense Industrial Base has continued needs for low-code/no-code solutions that provide advanced analytics visualizations, machine learning, self-service analytics, natural language queries, and augmented and artificial intelligence.
  • The Pyramid Platform received top ratings in leading analyst firm Gartner’s 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
  • Pyramid’s US Federal Practice is led by a team of experienced leaders, including Joe Fritsch, Director of Federal Sales; Peter Morris, Senior Director of Partner Channel, North America; Dave Henry, Senior Vice President, Strategic Alliances; Russ Cosentino, Regional Vice President Sales, North America, East; and Brian McCormac, Senior Vice President of Global Sales.

“Being added to the Tradewind Solutions Marketplace is a significant recognition of the quality and relevance of our platform to the current and future needs of the defense industry. The Pyramid Decision Intelligence Platform offers comprehensive capabilities to support government agencies’ AI/ML, digital, and data analytics needs, enabling them to make faster and more informed decisions,” said Joe Fritsch, Director of Federal Sales at Pyramid Analytics.

In October 2022, Pyramid announced a new business practice dedicated to the US federal market, led by Joe Fritsch, and a strategic partnership with Carahsoft, The Trusted Government IT Solutions Provider®. This new DoD marketplace listing has strengthened its commitment to providing critical decision intelligence to government agencies.

The Pyramid Decision Intelligence Platform is already used by other government agencies, including the U.S. Department of Veterans Affairs, where it provides advanced analytics capabilities to over 50,000 users to help the VA manage, assess, and deliver quality healthcare to veterans across all VA hospitals.

Pyramid’s addition to the Tradewind Solutions Marketplace marks another significant milestone in the company’s dedication to helping U.S. federal civilian, defense, and intelligence agencies expand and optimize their use of data-informed decision intelligence at scale.

About Pyramid Analytics

Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.

Pyramid Analytics USA is the U.S.-based subsidiary of Pyramid Analytics B.V. that is incorporated in Amsterdam with regional operations in global innovation and business centers, including New York City, London, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.

For additional information on the Pyramid offerings in the Tradewind Solutions Marketplace, interested Government parties can log in at https://www.tradewindai.com/ and search for “Pyramid Analytics.” Registration is required.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye